ZIOPHARM Oncology, Inc.
Jan 4, 2017
PDF

ZIOPHARM to Present at the 35th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2017 at 7:30 a.m. PT.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immunotherapy programs, in collaboration with Intrexon Corporation (NYSE:XON), includes viral and non-viral approaches to deliver viral and cell-based therapeutic candidates for investigational treatment of liquid and solid tumors. The Company is advancing programs in multiple stages of development including Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to precisely modulate gene expression. The Company's pipeline includes adenoviral- and cell-based therapeutics in both clinical and preclinical testing, some of which are being advanced in collaboration with MD Anderson Cancer Center.

 

Contact:
Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
locchiogrosso@ziopharm.com

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com